HealthcareServices

Type 1 Diabetes Industry Growth Insights: Revenue Forecast to 2030

March 3, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the type 1 diabetes market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Type 1 Diabetes Market reach by 2030 starting from 2026 levels?

The market for type 1 diabetes has seen rapid expansion over recent years. Its valuation is set to increase from $13.5 billion in 2025 to $15.27 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.1%. This historical growth can be ascribed to several factors, including the better availability of insulin analogs, an increase in diagnosis rates among pediatric populations, the establishment of more diabetes specialty care centers, greater awareness regarding autoimmune diabetes, and advancements in glucose monitoring technologies.

The type 1 diabetes market size is anticipated to experience substantial growth in the upcoming years, with projections indicating it will reach $25.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.9%. This expansion throughout the forecast period can be linked to the increasing adoption of closed-loop insulin delivery systems, growing investments in immunotherapy research, an intensifying focus on disease-modifying treatments, the broadening of digital platforms for diabetes management, and the rising demand for patient-centric care models. Noteworthy trends expected during this period include the wider integration of continuous glucose monitoring systems, an increase in the utilization of insulin pump technologies, a greater emphasis on personalized insulin therapy, the expansion of combination therapy approaches, and an enhanced focus on early diagnosis and disease management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12872&type=smp

Which Drivers Are Influencing Long-Term Growth In The Type 1 Diabetes Market?

The expansion of the Turner syndrome market moving forward is anticipated to be fueled by the increasing female population. The female population refers to the total count of females inhabiting a specific region or globally at a particular point in time. This increase in the female population is primarily attributed to a higher female life expectancy, which is supported by advancements in healthcare systems and shifts in demographics. The Turner syndrome market offers assistance to the female population through providing growth hormone therapy, estrogen replacement, and multidisciplinary care, all of which contribute to improved physical development, reproductive health, and long-term well-being. For example, in March 2024, the U.S. Census Bureau, a U.S.-based federal government agency, reported that the United States had 0.168 billion females as of July 2022. Moreover, in 2023, according to Statistics Canada, a Canada-based national statistics agency, the number of females aged 15–64 grew to 0.01304 billion. Thus, the rising female population is a significant driver for the growth of the Turner syndrome market.

Which Segments Are Driving Activity In The Type 1 Diabetes Market?

The type 1 diabetes market covered in this report is segmented –

1) By Product Type: Rapid Acting Insulin Analogs, Long-Acting Insulin Analogs, Premix Insulin Analogs, Others Product Types

2) By Device: Insulin Pump, Insulin Pen, Blood Glucose Meter

3) By Application: Childrens, Adults

4) By End-User: Hospital, Research Institutes, Home Care

Subsegments:

1) By Rapid Acting Insulin Analogs: Insulin Lispro, Insulin Aspart, Insulin Glulisine

2) By Long-Acting Insulin Analogs: Insulin Detemir, Insulin Glargine, Insulin Degludec

3) By Premix Insulin Analogs: Premixed Insulin Lispro, Premixed Insulin Aspart, Premixed Insulin Glargine

4) By Other Product Types: Insulin Pumps, Continuous Glucose Monitoring Systems, Non-Insulin Medications, Combination Therapies

What Upcoming Trends Are Likely To Define The Future Path Of The Type 1 Diabetes Market?

Companies within the type 1 diabetes market are increasingly concentrating on developing advanced therapeutic options, such as allogeneic islet cell transplantation, to provide functional beta-cell replacement and lessen patients’ reliance on insulin. Allogeneic islet cell transplantation involves infusing donor pancreatic islet cells into the patient’s hepatic portal vein, aiming to restore the body’s own insulin production and reduce both the frequency of hypoglycemic episodes and the need for insulin injections. As an illustration, in June 2023, CellTrans Inc., a US-based biotechnology company, received authorization from the U.S. Food and Drug Administration (FDA) for Lantidra (donislecel), which is the first cellular therapy designed to treat patients with type 1 diabetes. This approval signifies a major advancement in regenerative medicine, presenting a potential long-term treatment choice for individuals with type 1 diabetes who face challenges with insulin dependence. Lantidra operates by substituting the insulin-producing cells destroyed by the immune system, thereby striving to re-establish the body’s innate capacity to regulate blood glucose levels.

Which Key Market Players Are Investing In Expansion And Innovation Within The Type 1 Diabetes Market?

Major companies operating in the type 1 diabetes market are Johnson and Johnson Limited, Merck and Co. Inc., Sanofi-Aventis LLC, Abbott Laboratories, Medtronic Plc, Eli Lilly and Co Ltd, Novo Nordisk A/S, Dexcom Inc, Insulet Corporation, Tandem Diabetes Care Inc, Adaptive Biotechnologies Corporation, Xeris Pharmaceuticals Inc, MannKind Corporation, Biocon Ltd, Virta Health Corp, Bigfoot Biomedical Inc, ViaCyte Inc, Beta Bionics Inc, Adocia SA, Senseonics Holdings Inc, Zealand Pharmaceuticals A/S, Provention Bio Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Type 1 Diabetes Market?

North America was the largest region in the type 1 diabetes market in 2025. The regions covered in the type 1 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Type 1 Diabetes Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12872&type=smp

Browse Through More Reports Similar to the Global Type 1 Diabetes Market 2026, By The Business Research Company

Digital Diabetes Management Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-diabetes-management-global-market-report

Type 2 Diabetes Market Report 2026

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Diabetes Care Devices Market 2026

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795